Integrative Phosphoproteomic and Proteomic Analysis of Candida albicans Exposed to Oxidative Stress

Víctor Arribas1, Ana Borrajo1, María Luisa Hernáez2

  • 1Department of Microbiology and Parasitology, Faculty of Pharmacy, Complutense University of Madrid (UCM), 28040 Madrid, Spain.

PubMed

Insights

Candida albicans, a WHO high-priority pathogen, faces limited treatments. This study used DDA-MS to uncover new antifungal targets by analyzing protein and phosphorylation changes during oxidative stress response.

Area of Science:

  • Microbiology
  • Biochemistry
  • Molecular Biology

Background:

  • Candida albicans is a WHO-identified high-priority pathogen causing invasive fungal infections.
  • Limited antifungal treatments necessitate the discovery of novel therapeutic targets.
  • Oxidative stress significantly impacts C. albicans survival and virulence.

Purpose of the Study:

  • To investigate the phosphoproteomics and proteomics of C. albicans under oxidative stress.
  • To identify key proteins and phosphorylation events involved in the late-stage stress response.
  • To discover new potential antifungal targets and understand their mechanisms.

Main Methods:

  • Utilized Data-Dependent Acquisition Mass Spectrometry (DDA-MS) technology.
  • Analyzed both protein abundance and phosphorylation changes.
  • Applied 10 mM H2O2 treatment for 200 minutes to induce oxidative stress.

Main Results:

  • Identified and quantified significant changes in protein and phosphoprotein levels.
  • Discovered novel phosphorylation sites in kinases and transcription factors.
  • Cdc5-reduced phosphorylation linked to G2 cell cycle arrest; Kis1 involved in ROS scavenging; Gzf3-decreased phosphorylation crucial for survival.

Conclusions:

  • DDA-MS is effective for identifying novel proteins and phosphorylation sites in C. albicans stress response.
  • Specific kinases (Cdc5, Kis1) and transcription factors (Gzf3) play critical roles in oxidative stress adaptation.
  • Findings provide potential new targets for antifungal drug development against C. albicans.